Please use this identifier to cite or link to this item:
Title: Synchrotron microbeam radiotherapy evokes a different early tumor immunomodulatory response to conventional radiotherapy in EMT6.5 mammary tumors.
Austin Authors: Yang, Yuqing;Swierczak, Agnieszka;Ibahim, Mohammad;Paiva, Premila;Cann, Leonie;Stevenson, Andrew W;Crosbie, Jeffrey C;Anderson, Robin L ;Rogers, Peter A W
Affiliation: Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Australia
MRC Centre for Reproductive Health, Queen's Medical Research Institute, The University of Edinburgh, UK
Department of Obstetrics & Gynaecology, University of Melbourne, Royal Women's Hospital, Parkville, Australia
The Imaging and Medical Beamline, Australian Synchrotron, Clayton, Australia
CSIRO Materials Science & Engineering, Clayton, Australia
School of Science, RMIT University, Melbourne, Australia
Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Jalan Hospital, Selangor, Malaysia
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia
Issue Date: Apr-2019 2019-01-22
Publication information: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2019; 133: 93-99
Abstract: Synchrotron microbeam radiation therapy (MRT) is a new, evolving form of radiotherapy that has potential for clinical application. Several studies have shown in preclinical models that synchrotron MRT achieves equivalent tumor control to conventional radiotherapy (CRT) but with significantly reduced normal tissue damage. To explore differences between these two modalities, we assessed the immune cell infiltrate into EMT6.5 mammary tumors after CRT and MRT. CRT induced marked increases in tumor-associated macrophages and neutrophils while there were no increases in these populations following MRT. In contrast, there were higher numbers of T cells in the MRT treated tumors. There were also increased levels of CCL2 by immunohistochemistry in tumors subjected to CRT, but not to MRT. Conversely, we found that MRT induced higher levels of pro-inflammatory genes in tumors than CRT. Our data are the first to demonstrate substantial differences in macrophage, neutrophil and T cell numbers in tumors following MRT versus CRT, providing support for the concept that MRT evokes a different immunomodulatory response in tumors compared to CRT.
DOI: 10.1016/j.radonc.2019.01.006
ORCID: 0000-0002-6841-7422
PubMed URL: 30935588
Type: Journal Article
Subjects: Conventional radiotherapy
Immune infiltrate
Mammary tumors
Myeloid cells
Synchrotron microbeam radiotherapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 1, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.